Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations
Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.
Could TRexBio’s Treg bet crack the next big frontier in atopic dermatitis?
Atopic dermatitis has more drugs, but not enough durable control. TRexBio’s TRB-061 tests whether tissue Tregs can change that.
Can Nektar’s 52-week REZOLVE-AA update strengthen the case for rezpegaldesleukin in alopecia areata?
Nektar will discuss 52-week REZOLVE-AA data for rezpegaldesleukin on April 20. Find out what the alopecia areata catalyst could mean.
Citius Oncology tests LYMPHIR before CAR-T therapy in DLBCL. Does immune modulation improve response durability?
Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
What Kainova Therapeutics’ latest financing reveals about the future of CCR8-targeted cancer therapies
Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.
Can CK0804 overcome JAK inhibitor resistance in myelofibrosis and reshape the Treg cell therapy landscape?
Cellenkos, Inc., a clinical-stage biotechnology company developing allogeneic regulatory T cell (Treg) therapies, has unveiled new data from its investigational product CK0804, presented at the 67th American Society of Hematology (ASH) Annual Meeting. The findings highlight the potential of a dose-intensive regimen of CK0804 to reduce spleen volume, improve symptoms, and lower transfusion dependence in […]